1. Home
  2. DH vs ANIX Comparison

DH vs ANIX Comparison

Compare DH & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Definitive Healthcare Corp.

DH

Definitive Healthcare Corp.

HOLD

Current Price

$0.96

Market Cap

107.6M

Sector

Technology

ML Signal

HOLD

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$2.97

Market Cap

102.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DH
ANIX
Founded
2011
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
107.6M
102.6M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
DH
ANIX
Price
$0.96
$2.97
Analyst Decision
Hold
Strong Buy
Analyst Count
5
3
Target Price
$3.08
$8.67
AVG Volume (30 Days)
243.0K
113.0K
Earning Date
05-07-2026
05-27-2026
Dividend Yield
N/A
N/A
EPS Growth
63.28
12.82
EPS
N/A
N/A
Revenue
$241,521,000.00
$210,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$0.74
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.89
$2.44
52 Week High
$4.70
$5.46

Technical Indicators

Market Signals
Indicator
DH
ANIX
Relative Strength Index (RSI) 42.22 51.78
Support Level $0.93 $2.74
Resistance Level $1.19 $3.11
Average True Range (ATR) 0.08 0.18
MACD 0.00 -0.01
Stochastic Oscillator 25.01 36.88

Price Performance

Historical Comparison
DH
ANIX

About DH Definitive Healthcare Corp.

Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

Share on Social Networks: